High-Intensity Statins have been the treatment of choice for ASCVD. However, the recent non-inferiority RACING study evaluates the role of combination moderate-dose statin plus ezetimibe to high-dose statin in ASCVD. Host Geoff Wall breaks down another potential GameChanger in Pharmacotherapy.

The GameChanger
Combination moderate-dose statins plus ezetimibe may be non-inferior to high-dose statins – and have the benefit of better tolerability.


Show Segments 
00:00 – Introductions 
01:55 – Long-Term Efficacy and Safety of Moderate Intensity Statins with Ezetimibe 
02:55 – Statins and Ezetimibe in ASCVD  
13:52 – The GameChanger 
20:50 – Connecting to Practice  
22:01 – Closing Remarks 

Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

References and resources:

Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial

Redeem your CPE or CME credit

• CPE (Pharmacist) 
• CME (Physician) 

Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) 

• Pharmacists: Get a Membership 
• Prescribers: Get a Membership 

Continuing Education Information:
Learning Objectives:
1. Discuss the RACING study results comparing moderate-dose statin plus ezetimibe to high-dose statins
2. Describe the known ‘nocebo’ effect of muscle-related statin adverse effects.
 

0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-22-310-H01-P
Initial release date: 09/05/22
Expiration date: 09/05/2023
Additional CPE & CME details can be found here 

Follow CEimpact on Social Media:
LinkedIn
Instagram